Q1 EPS Estimate for Monopar Therapeutics Boosted by Analyst

Chronological Source Flow
Back

AI Fusion Summary

Brookline Capital Markets raised Monopar Therapeutics Q1 2026 EPS to $0.80 from $0.81; HC Wainwright cut Rein Therapeutics FY2026 EPS to $1.63 from $0.80; Northland Securities lowered Amprius Technologies Q1 2027 EPS to $0.00 from $0.04.
#MONOPAR_THERAPEUTICS #REIN_THERAPEUTICS #AMPRIUS_TECHNOLOGIES #ANALYST #EPS #Q1 #FY2026 #FY2027
08/04 08:11 defenseworld.net
3 Πηγές

Q1 EPS Estimate for Monopar Therapeutics Boosted by Analyst

Monopar TherapeuticsBrookline Capital MarketsEPS estimateQ1 2026FY2026 forecastNASDAQ MNPR
08/04 08:28 defenseworld.net

FY2026 EPS Estimate for Rein Therapeutics Lowered by Analyst

ANALYST ARTICLES - ESTIMATESCOMPANIESEARTHQUAKEPOLITICS
08/04 09:00 defenseworld.net

Q1 EPS Estimate for Amprius Technologies Lowered by Analyst

ANALYST ARTICLES - ESTIMATESCOMPANIESPOLITICS
Comments
Loading...
0